Hongmei JIA

Prof. Hongmei JIA

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZLZijing Li
Zijing Li
MCMengchao Cui
Mengchao Cui
JDJiapei Dai
Jiapei Dai
XWXuedan Wang
Xuedan Wang
PYPingrong Yu
Pingrong Yu
BLBoli Liu
Boli Liu

13 September 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MCMengchao Cui
Mengchao Cui
XWXuedan Wang
Xuedan Wang
PYPingrong Yu
Pingrong Yu
JZJinming Zhang
Jinming Zhang
ZLZijing Li
Zijing Li
BLBoli Liu
Boli Liu

1 June 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YYYanping Yang
Yanping Yang
MCMengchao Cui
Mengchao Cui
BJBing Jin
Bing Jin
XWXuedan Wang
Xuedan Wang
ZLZijing Li
Zijing Li
BLBoli Liu
Boli Liu

8 May 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YHYingfang He
Yingfang He
FXFang Xie
Fang Xie
JYJiajun Ye
Jiajun Ye
WDWinnie Deuther-Conrad
Winnie Deuther-Conrad
BCBixiao Cui
Bixiao Cui
HJHongmei JIA
Hongmei JIA

1 January 2019 in Neuroscience Letters
Verified
Journal Article
Closed access
HJHongmei JIA
Hongmei JIA
YZYing Zhang
Ying Zhang
YHYiyun Huang
Yiyun Huang

Verified
Journal Article
Open access
PDF file
WTWang Tao
Wang Tao
HJHongmei JIA
Hongmei JIA
Sigma (σ) receptors are a class of unique proteins with two subtypes: the sigma-1 (σ1) receptor which is situated at the mitochondria-associated endoplasmic reticulum (ER) membrane (MAM), and the sigma-2 (σ2) receptor, located in the ER-resident membrane. Increasing evidence indicates the involvement of both σ1 and σ2 receptors in the pathogenesis of Alzheimer’s disease (AD), and thus these receptors represent two potentially effective biomarkers for emerging AD therapies. The availability of optimal radioligands for positron emission tomography (PET) neuroimaging of the σ1 and σ2 receptors in humans will provide tools to monitor AD progression and treatment outcomes. In this review, we first summarize the significance of both receptors in the pathophysiology of AD and highlight AD therapeutic strategies related to the σ1 and σ2 receptors. We then survey the potential PET radioligands, with an emphasis on the requirements of optimal radioligands for imaging the σ1 or σ2 receptors in humans. Finally, we discuss current challenges in the development of PET radioligands for the σ1 or σ2 receptors, and the opportunities for neuroimaging to elucidate the σ1 and σ2 receptors as novel biomarkers for early AD diagnosis, and for monitoring of disease progression and AD drug efficacy.